Your browser doesn't support javascript.
loading
Development and assessment of a brief screening tool for psychosis in dementia.
Cummings, Jeffrey L; Ismail, Zahinoor; Dickerson, Bradford C; Ballard, Clive; Grossberg, George; McEvoy, Bradley; Foff, Erin; Atri, Alireza.
Afiliação
  • Cummings JL; Chambers-Grundy Center for Transformative Neuroscience Department of Brain Health School of Integrated Health Sciences University of Nevada Las Vegas Las Vegas Nevada USA.
  • Ismail Z; Hotchkiss Brain Institute University of Calgary O'Brien Institute for Public Health University of Calgary Calgary Alberta Canada.
  • Dickerson BC; Harvard Medical School Massachusetts General Hospital Boston Massachusetts USA.
  • Ballard C; The University of Exeter Medical School Exeter UK.
  • Grossberg G; St. Louis University School of Medicine St. Louis Missouri USA.
  • McEvoy B; Acadia Pharmaceuticals Inc. San Diego California USA.
  • Foff E; Acadia Pharmaceuticals Inc. San Diego California USA.
  • Atri A; Banner Sun Health Research Institute Banner Health Sun City Arizona USA.
Alzheimers Dement (Amst) ; 13(1): e12254, 2021.
Article em En | MEDLINE | ID: mdl-34934801
ABSTRACT

INTRODUCTION:

Hallucinations and delusions (H+D) are common in dementia, but screening for these symptoms-especially in busy clinical practices-is challenging.

METHODS:

Six subject matter experts developed the DRP3™ screen, a novel valid tool to detect H+D in dementia, assessed its content validity through alignment with DRP reference assessments (Scale for the Assessment of Positive Symptoms-Hallucinations + Delusions, Neuropsychiatric Inventory-Questionnaire, International Psychogeriatric Association Criteria), and retrospectively investigated its ability to detect H+D in HARMONY trial (NCT03325556) enrollees.

RESULTS:

All items from three reference assessments demonstrated significant agreement with the DRP3 screen among raters (P < .0001). Retrospectively applying the DRP3 screen to HARMONY identified all (N = 392) trial enrollees.

DISCUSSION:

The DRP3 screen, comprising three yes/no questions, is a content-valid tool for detecting H+D in dementia that aligned with current reference assessments and successfully identified trial participants when retrospectively applied to a completed trial. Within busy practice constraints, the DRP3 screen provides a brief tool for sensitive detection of H+D in patients with dementia.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Idioma: En Revista: Alzheimers Dement (Amst) Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Idioma: En Revista: Alzheimers Dement (Amst) Ano de publicação: 2021 Tipo de documento: Article